Zenpep Shortage: What Providers and Prescribers Need to Know in 2026

Patients with exocrine pancreatic insufficiency (EPI) require consistent access to pancreatic enzyme replacement therapy (PERT) to maintain adequate nutritional status. When Zenpep (pancrelipase) is unavailable at local pharmacies, the consequences for patients can be rapid and severe — malabsorption, weight loss, and fat-soluble vitamin deficiencies can develop within days. This guide is designed for prescribers who need to manage Zenpep availability challenges for their patient panels in 2026.

Current Zenpep Availability Status

As of 2026, Zenpep is not listed on the FDA's national Drug Shortage Database. However, prescribers should be aware that the absence of a formal shortage designation does not reflect the real-world availability challenges patients experience. Zenpep is a brand-only, porcine-derived medication available in eight dose strengths (3,000–60,000 lipase units). Localized stock-outs — particularly for less common strengths — occur frequently and are not captured in federal shortage tracking systems.

The primary drivers of Zenpep availability problems are structural: brand-only status (no generic exists), multiple dose strengths requiring individual stocking, high per-patient volumes (patients may take 90–180+ capsules per month), and a porcine-based manufacturing supply chain with limited production redundancy.

The Clinical Risk of PERT Gaps for EPI Patients

Providers should counsel patients on the urgency of continuous PERT access. Even brief interruptions in pancrelipase therapy — as short as 2–3 days — can result in:

• Steatorrhea and osmotic diarrhea with rapid fluid and electrolyte loss
• Significant abdominal pain, bloating, and flatulence
• Accelerated weight loss and lean mass depletion
• Worsening deficiencies in fat-soluble vitamins A, D, E, and K
• In pediatric CF patients: impaired growth velocity and pulmonary function decline

Patients with pancreatic cancer, who often have cachexia and reduced nutritional reserve, are particularly vulnerable to PERT interruptions. Providers managing these patients should have a contingency plan in place before a supply gap occurs.

Switching Protocols: When and How to Transition Patients Off Zenpep

The FDA has explicitly stated that pancrelipase products (Zenpep, Creon, Pancreaze, Pertzye, Viokace) are not interchangeable and should not be substituted by pharmacists without a new prescription. Dose equivalency between products has not been formally established, and clinical performance may differ due to differences in enteric-coating technology, bead/microsphere size, and pH dissolution profiles.

Available PERT Alternatives to Zenpep

• Creon (AbbVie): Enteric-coated microspheres. Available in 3,000 / 6,000 / 12,000 / 24,000 / 36,000 / 60,000 lipase units. Approved for CF, chronic pancreatitis, pancreatectomy, other conditions. Most widely stocked PERT in U.S. pharmacies. Clinical data shows non-inferiority to Zenpep in fat absorption (84.1% vs 85.3% CFA in crossover trial).
• Pancreaze: Enteric-coated microtablets. Multiple strengths available. Approved for CF and other conditions. Similar mechanism to Zenpep; brand-only.
• Pertzye: Bicarbonate-buffered enteric-coated microspheres. May offer advantage in patients with low duodenal pH. Approved for CF and other conditions.
• Viokace: Non-enteric-coated tablet. Must co-administer with PPI. Approved for adults only; EPI due to chronic pancreatitis or pancreatectomy. Not approved for CF.

Dosing Guidance When Switching PERT Products

When transitioning a patient from Zenpep to an alternative PERT:

1. Start with the same total lipase units per meal as the patient's current Zenpep dose.
2. Educate the patient that the new product may feel different — stool consistency and GI comfort may shift as the new formulation is established.
3. Schedule a follow-up within 4–6 weeks to assess symptom control and adjust dose based on clinical response, coefficient of fat absorption (CFA), and weight.
4. Do not exceed 2,500 lipase units/kg/meal or 10,000 units/kg/day without clinical justification.

Practice-Level Strategies for Managing PERT Availability

• Counsel patients at every visit to maintain a 10-day supply buffer and refill proactively.
• Authorize 90-day supplies where clinically appropriate and covered by the patient's insurance. This reduces fill frequency and exposure to localized shortages.
• Document alternative PERT tolerance in the patient chart so that if Zenpep becomes unavailable, staff can rapidly provide a bridge prescription for an alternative already vetted for that patient.
• Recommend mail-order or specialty pharmacies for patients who have experienced repeated local stock-outs. These pharmacies typically maintain larger PERT inventories.
• Direct patients to medfinder. medfinder for providers is a service that calls local pharmacies to locate Zenpep in stock, saving patients hours of phone calls.

Patient Assistance and Savings Resources for Zenpep

For patients who have found Zenpep but face cost barriers, the following resources may help:

• Z-Save® (Nestlé Health Science): $0 for first fill, $30/refill for commercially insured patients. Not valid for Medicare/Medicaid. Phone: 1-833-742-0707.
• CF Patient Support Program: Parallel program for CF-related EPI patients. Visit www.ZENPEPCFProgram.com.
• HealthWell Foundation CF Fund: 1-800-675-8416. Income-based assistance for patients with CF.

Summary for Providers

Zenpep availability problems are structural, ongoing, and unlikely to be resolved in the short term. The most effective approach is proactive: counsel patients to maintain supply buffers, pre-authorize alternatives in the patient record, and direct patients to tools that can efficiently locate pharmacy stock. For a detailed operational guide, see our article on how to help your patients find Zenpep in stock.